Reply: Immunophenotypic prediction of TEL-AML1 rearrangement in childhood ALL

TO THE EDITOR
We read with interest the comments of Hrusak et al regarding our suggestion that immunophenotypic features might be used as a surrogate to predict TEL-AML1 negativity. 1 We are also aware of their own data suggesting that KOR-SA3544 expression could serve in a similar capacity to our suggested use of CD9 and CD20 expression; 2 like them we are less concerned with debating the relative merits of using one set of markers over another and more with the general point of whether screening is a valid strategy.
We agree with many of the points raised by the letter. Of course to be an effective approach any screening strategy must save more than it costs to perform; if molecular testing is cheaper than the cost of phenotyping and the latter adds no additional information it is not useful. We do not agree, however, as the letter suggests, that such a predictive test is useful only if it has a high prognostic value in and of itself. If cost effective, a screening strategy can be justified if it helps to identify a set of patients for further analysis and study. As immunophenotyping for lineage assignment is part of the routine investigation of newly diagnosed patients with ALL, it becomes especially attractive to look to this technology as such a screening tool.
In our case we can make a particularly strong argument for phenotypic screening. In our studies all phenotypic and molecular testing in childhood ALL is to be performed in the context of a comprehensive investigative protocol whereby patients will be assigned to treatment regimens based on molecular abnormalities along with traditional clinical risk factors. Moreover, one objective of the studies will be to investigate the significance of minimal residual disease, as detected by both flow and molecular methodologies. We have recently shown that a limited panel of antibodies can be used to detect MRD by flow in nearly all cases of B-precursor ALL. 3 This panel of antibodies in fact includes both CD9 and CD20 along with CD19, so that in the course of characterizing the phenotypic abnormalities useful for monitoring patients we have all the information needed to predict the TEL-AML1 rearrangement. Thus, once the screening assays are done for lineage assessment, we have obtained valuable information, at no additional cost, that allows us to make predictions about the presence or absence of specific molecular genetic abnormalities. While we agree that in terms of material costs for molecular testing, the majority of the expense lies in the sample preparation and extraction of nucleic acid, there is still a not inconsiderable marginal cost of primer amplification and hybridization which ranges up to $10-20 per sample without even considering personnel costs. 4 Thus, the elimination of unnecessary testing on 57% of patients does amount to a significant saving when more than 700 children per year with Bprecursor ALL are tested.
Hrusak et al also point out that the suitability of a screening procedure depends on having an appropriately high negative predictive value, a point with which we also agree. We would further add the condition that how high this has to be depends to some extent on the consequences of a false negative. In the case of the TEL-AML1 rearrangement, our current study plans are to treat such patients with less intensive therapy than they would otherwise receive. The small number of patients per year whom we fail to detect would thus receive standard therapy similar to that which such patients have received on most studies in the past on which they have fared very well. Thus, we feel very differently about missing this small group of patients compared to a similar number of patients with, for example, the t(9;22) who would run a serious risk of undertreatment.
In summary, while we agree with many of the philosophical points raised by Hrusak et al, and would certainly not endorse considering phenotypic information as the equivalent of a molecular result, we do believe that if well thought-out, a screening strategy can be cost-effective and permit limited resources to be used most efficiently to further our understanding of the biology of childhood ALL.
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